AUTL vs. IMVT, SWTX, ACLX, APGE, DNLI, IOVA, TWST, VCEL, IMCR, and CGON
Should you be buying Autolus Therapeutics stock or one of its competitors? The main competitors of Autolus Therapeutics include Immunovant (IMVT), SpringWorks Therapeutics (SWTX), Arcellx (ACLX), Apogee Therapeutics (APGE), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), Twist Bioscience (TWST), Vericel (VCEL), Immunocore (IMCR), and CG Oncology (CGON). These companies are all part of the "biological products, except diagnostic" industry.
Autolus Therapeutics (NASDAQ:AUTL) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends.
Autolus Therapeutics has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.
Immunovant's return on equity of -53.40% beat Autolus Therapeutics' return on equity.
Autolus Therapeutics received 108 more outperform votes than Immunovant when rated by MarketBeat users. However, 76.55% of users gave Immunovant an outperform vote while only 67.18% of users gave Autolus Therapeutics an outperform vote.
72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by insiders. Comparatively, 4.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Autolus Therapeutics presently has a consensus price target of $8.70, suggesting a potential upside of 107.64%. Immunovant has a consensus price target of $49.00, suggesting a potential upside of 92.99%. Given Autolus Therapeutics' higher possible upside, research analysts clearly believe Autolus Therapeutics is more favorable than Immunovant.
Autolus Therapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Immunovant had 23 more articles in the media than Autolus Therapeutics. MarketBeat recorded 26 mentions for Immunovant and 3 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.72 beat Immunovant's score of 0.58 indicating that Autolus Therapeutics is being referred to more favorably in the media.
Summary
Autolus Therapeutics beats Immunovant on 11 of the 16 factors compared between the two stocks.
Get Autolus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Autolus Therapeutics Competitors List
Related Companies and Tools
